TY - JOUR
T1 - International Society of Urological Pathology (ISUP) Consensus Conference on Precursor Lesions
T2 - Working Group 4 Precursor Lesions of Testis Results of a Premeeting Survey
AU - The Members of the ISUP GU Cancer Precursor Consensus Panel
AU - Bremmer, Felix
AU - Colecchia, Maurizio
AU - Collins, Katrina
AU - Acosta, Andres M.
AU - Gupta, Sounak
AU - Gordetsky, Jennifer B.
AU - Maclean, Fiona
AU - Meyts, Ewa Rajpert De
AU - Dieckmann, Klaus Peter
AU - Kaushal, Seema
AU - Srigley, John R.
AU - Adra, Nabil
AU - Gilligan, Timothy
AU - Daugaard, Gedske
AU - Looijenga, Leendert H.J.
AU - Kristiansen, Glen
AU - Cheng, Liang
AU - Tickoo, Satish K.
N1 - Copyright © 2026 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2026/6/1
Y1 - 2026/6/1
N2 - According to the current WHO classification, noninvasive germ cell neoplasia of the testis comprises germ cell neoplasia in situ (GCNIS), specific forms of intratubular germ cell neoplasia, and gonadoblastoma. Because type II germ cell tumors (GCT, type II) arise from GCNIS, accurate detection of precursor lesions is diagnostically important. In preparation for the 2024 International Society of Urological Pathology (ISUP) Consensus Conference on genitourinary precursor lesions, which took place in Florence, Italy, an anonymous survey was distributed to ISUP members to assess current diagnostic practices regarding testicular precursor lesions. The literature and current WHO classification affirm the significance of precursor lesions in testicular tumours. Working Group 4—Precursor Lesions of the Testis—focused on their practical application by individual pathologists rather than establishing consensus from scientific data. There is strong agreement that GCNIS is the preferred and appropriate term for GCT precursor lesions and that its presence should be reported in cases of invasive GCT. Respondents also agree that “seminoma with intratubular nonseminoma” is the appropriate terminology for seminoma with an associated noninvasive nonseminomatous (embryonal carcinoma, yolk sac tumor, trophoblasts, or teratoma) component. Most pathologists prefer to use OCT3/4 as the primary immunohistochemical marker, and a panel was generally not considered necessary. No consensus is reached regarding the requirement for immunohistochemistry to confirm GCT precursor lesions in the testis. Three questions remain open: the value of subtyping intratubular lesions, the immunohistochemical approach to gonadoblastoma, and the criteria distinguishing Sertoli cell nodules from Sertoli cell tumors.
AB - According to the current WHO classification, noninvasive germ cell neoplasia of the testis comprises germ cell neoplasia in situ (GCNIS), specific forms of intratubular germ cell neoplasia, and gonadoblastoma. Because type II germ cell tumors (GCT, type II) arise from GCNIS, accurate detection of precursor lesions is diagnostically important. In preparation for the 2024 International Society of Urological Pathology (ISUP) Consensus Conference on genitourinary precursor lesions, which took place in Florence, Italy, an anonymous survey was distributed to ISUP members to assess current diagnostic practices regarding testicular precursor lesions. The literature and current WHO classification affirm the significance of precursor lesions in testicular tumours. Working Group 4—Precursor Lesions of the Testis—focused on their practical application by individual pathologists rather than establishing consensus from scientific data. There is strong agreement that GCNIS is the preferred and appropriate term for GCT precursor lesions and that its presence should be reported in cases of invasive GCT. Respondents also agree that “seminoma with intratubular nonseminoma” is the appropriate terminology for seminoma with an associated noninvasive nonseminomatous (embryonal carcinoma, yolk sac tumor, trophoblasts, or teratoma) component. Most pathologists prefer to use OCT3/4 as the primary immunohistochemical marker, and a panel was generally not considered necessary. No consensus is reached regarding the requirement for immunohistochemistry to confirm GCT precursor lesions in the testis. Three questions remain open: the value of subtyping intratubular lesions, the immunohistochemical approach to gonadoblastoma, and the criteria distinguishing Sertoli cell nodules from Sertoli cell tumors.
KW - OCT3/4
KW - germ cell neoplasia in situ
KW - germ cell tumor
KW - gonadoblastoma
KW - immunohistochemistry
KW - Predictive Value of Tests
KW - Humans
KW - Terminology as Topic
KW - Male
KW - Precancerous Conditions/pathology
KW - Consensus
KW - Neoplasms, Germ Cell and Embryonal/pathology
KW - Testicular Neoplasms/pathology
KW - Biomarkers, Tumor/analysis
KW - Carcinoma in Situ/pathology
KW - Surveys and Questionnaires
KW - Seminoma/pathology
KW - Gonadoblastoma/pathology
KW - Urology/standards
UR - https://www.scopus.com/pages/publications/105035597380
UR - http://www.ncbi.nlm.nih.gov/pubmed/41724745
UR - https://www.mendeley.com/catalogue/e1382a68-9b0c-352d-9f43-c652247d3ae5/
U2 - 10.1097/PAS.0000000000002523
DO - 10.1097/PAS.0000000000002523
M3 - Article
C2 - 41724745
AN - SCOPUS:105035597380
SN - 0147-5185
VL - 50
JO - American Journal of Surgical Pathology
JF - American Journal of Surgical Pathology
IS - 6
ER -